Combined PET Imaging and Diffusion-Weighted Imaging of Intermediate and High-Risk Primary Prostate Carcinomas with Simultaneous [18F] Choline PET/MRI

Purpose To characterize intermediate and high-risk prostate carcinomas with measurements of standardized uptake values (SUVs) and apparent diffusion coefficient (ADC) values by means of simultaneous [18F] choline PET/MRI. Materials and Methods 35 patients with primary prostate cancer underwent simultaneous [18F] choline PET/MRI. From these, 21 patients with an intermediate and high risk constellation who were not under ongoing hormonal therapy were included. Altogether 32 tumor lesions with a focal uptake of [18F] choline could be identified. Average ADC values (ADCaver) minimum ADC values (ADCmin) as well as maximum and mean SUVs (SUVmax, SUVmean) of tumor lesions were assessed with volume-of-interest (VOI) and Region-of-interest (ROI) measurements. As a reference, also ADCaver, ADCmin and SUVmax and SUVmean of non-tumorous prostate tissue were measured. Statistical analysis comprised calculation of descriptive parameters and calculation of Pearson’s product moment correlations between ADC values and SUVs of tumor lesions. Results Mean ADCaver and ADCmin of tumor lesions were 0.94±0.22×10−3 mm2/s and 0.65±0.21×10−3 mm2/s, respectively. Mean SUVmax and SUVmean of tumor lesions were 6.3±2.3 and 2.6±0.8, respectively. These values were in each case significantly different from the reference values (p<0.001). There was no significant correlation between the measured SUVs and ADC values (SUVmax vs. ADCaver: R = −0.24, p = 0.179; SUVmax vs. ADCmin: R = −0.03, p = 0.877; SUVmean vs. ADCaver: R = −0.27, p = 0.136; SUVmean vs. ADCmin: R = −0.08, p = 0.679). Conclusion Both SUVs and ADC values differ significantly between tumor lesions and healthy tissue. However, there is no significant correlation between these two parameters. This might be explained by the fact that SUVs and ADC values characterize different parts of tumor biology.

[1]  G. Tomasi,et al.  Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer , 2014, Nuclear medicine communications.

[2]  Eisaku Ito,et al.  Apparent diffusion coefficient value as a biomarker reflecting morphological and biological features of prostate cancer , 2014, International Urology and Nephrology.

[3]  Zhaoqin Huang,et al.  Diffusion-weighted imaging of prostate cancer on 3T MR: Relationship between apparent diffusion coefficient values and Ki-67 expression. , 2013, Academic radiology.

[4]  M. Haider,et al.  The expanding role of MRI in prostate cancer. , 2013, AJR. American journal of roentgenology.

[5]  C. Geppert,et al.  Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI. , 2013, AJR. American journal of roentgenology.

[6]  P. V. van Diest,et al.  Why prostate tumour delineation based on apparent diffusion coefficient is challenging: An exploration of the tissue microanatomy , 2013, Acta oncologica.

[7]  K. Sugimura,et al.  Do apparent diffusion coefficient (ADC) values obtained using high b-values with a 3-T MRI correlate better than a transrectal ultrasound (TRUS)-guided biopsy with true Gleason scores obtained from radical prostatectomy specimens for patients with prostate cancer? , 2013, European journal of radiology.

[8]  Sibylle Ziegler,et al.  Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  Felix Nensa,et al.  Simultaneous 18F Choline Positron Emission Tomography/Magnetic Resonance Imaging of the Prostate: Initial Results , 2013, Investigative radiology.

[10]  Thomas Hambrock,et al.  Differentiation of prostatitis and prostate cancer by using diffusion-weighted MR imaging and MR-guided biopsy at 3 T. , 2013, Radiology.

[11]  Karl-Olof Lovblad,et al.  Functional imaging of head and neck squamous cell carcinoma with diffusion-weighted MRI and FDG PET/CT: quantitative analysis of ADC and SUV , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  M. Schwaiger,et al.  [[¹¹C]choline as a pharmacodynamic marker for docetaxel therapy. Response assessment in a LNCaP prostate cancer xenograft mouse model]. , 2013, Nuklearmedizin. Nuclear medicine.

[13]  T. Schuster,et al.  Ansprechen auf eine Docetaxel-therapie im LNCaP-Prostata-karzinom-Xenograft-Mausmodell , 2013, Nuklearmedizin.

[14]  M. Schwaiger,et al.  [11C]choline as a pharmacodynamic marker for docetaxel therapy , 2013 .

[15]  James Nagarajah,et al.  Evaluation of the PET component of simultaneous [18F]choline PET/MRI in prostate cancer: comparison with [18F]choline PET/CT , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  J. Bussink,et al.  Diffusion-weighted MR imaging in liver metastases of colorectal cancer: reproducibility and biological validation , 2013, European Radiology.

[17]  Jian-Rong Xu,et al.  Usefulness of diffusion-weighted magnetic resonance imaging in the diagnosis of prostate cancer. , 2012, Academic radiology.

[18]  L. Bains,et al.  Therapy response with diffusion MRI: an update , 2012, Cancer imaging : the official publication of the International Cancer Imaging Society.

[19]  M. Nomoto,et al.  FDG PET/CT and Diffusion-Weighted Imaging of Head and Neck Squamous Cell Carcinoma: Comparison of Prognostic Significance Between Primary Tumor Standardized Uptake Value and Apparent Diffusion Coefficient , 2012, Clinical nuclear medicine.

[20]  G. Bauman,et al.  18F-fluorocholine for prostate cancer imaging: a systematic review of the literature , 2011, Prostate Cancer and Prostatic Diseases.

[21]  Celia P. Corona-Villalobos,et al.  Oncologic applications of diffusion‐weighted MRI in the body , 2012, Journal of magnetic resonance imaging : JMRI.

[22]  H. Thoeny,et al.  Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature. , 2012, European urology.

[23]  Z. Bhujwalla,et al.  Choline metabolism in malignant transformation , 2011, Nature Reviews Cancer.

[24]  S. Hazell,et al.  Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression , 2011, Clinical Cancer Research.

[25]  K. Chang,et al.  Correlation of 18F-FDG Uptake with Apparent Diffusion Coefficient Ratio Measured on Standard and High b Value Diffusion MRI in Head and Neck Cancer , 2011, The Journal of Nuclear Medicine.

[26]  Manish Kakar,et al.  Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: a preclinical study , 2011, Radiation oncology.

[27]  F. Mottaghy,et al.  Response assessment of hormonal therapy in prostate cancer by [11C] choline PET/CT. , 2010, Clinical nuclear medicine.

[28]  A. Jemal,et al.  Global Patterns of Cancer Incidence and Mortality Rates and Trends , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[29]  Brian D Ross,et al.  Predicting and monitoring cancer treatment response with diffusion‐weighted MRI , 2010, Journal of magnetic resonance imaging : JMRI.

[30]  C. Kim,et al.  Assessment of response to radiotherapy for prostate cancer: value of diffusion-weighted MRI at 3 T. , 2010, AJR. American journal of roentgenology.

[31]  P. Waldenberger,et al.  18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. , 2010, Radiology.

[32]  Nassir Navab,et al.  Tissue Classification as a Potential Approach for Attenuation Correction in Whole-Body PET/MRI: Evaluation with PET/CT Data , 2009, Journal of Nuclear Medicine.

[33]  R. Tiling,et al.  Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  R. Rosell,et al.  Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. , 2002, Biochemical and biophysical research communications.

[35]  S B Malkowicz,et al.  Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. , 2001, The Journal of urology.